CGTX: the cash flow

MyFinsight

For the year ending 2025-12-31, CGTX had $11.991M increase in cash & cash equivalents over the period.

Cash Flow	2025-12-31
Grant income	23.406
Clinical programs	25.133
R&d personnel costs	7.743
Preclinical programs	0.446
Manufacturing	2.543
Other research and development expenses	0.23
General and administrative expenses (excluding equity-based compensation)	9.617
Equity-based compensation	2.087
Other segment items	-0.906
Net loss	-23.487
Depreciation and amortization	0.036
Equity-based compensation	2.087
Amortization of right-of-use assets	0.192
Realized loss on sale of property and equipment	-0.041
Grant receivables	7.237
Prepaid expenses and other assets	-1.173
Accounts payable and accrued expenses	3.51
Deferred grant income and other liabilities	-0.699
Operating lease liabilities	-0.204
Net cash used in operating activities	-24.588
Proceeds from sale of property and equipment	0.009
Net cash used in investing activities	0.009
Proceeds from issuance of common stock-Registered Direct Offering	27.89
Proceeds from issuance of common stock-At Market Offering	9.126
Proceeds from the exercise of common stock options	0.071
Payment of employee withholding taxes on vested restricted stock units	0.164
Payments on loan payable	0.353
Net cash provided by financing activities	36.57
Net increase (decrease) in cash, cash equivalents, and restricted cash equivalents	11.991
Cash, cash equivalents, and restricted cash equivalents - beginning of period	25.009
Cash, cash equivalents, and restricted cash equivalents - end of period	37

Unit: Million (M) dollars (except for numbers of shares and EPS).